Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

GT Biopharma, Inc. GTBP

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-28.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2020 · Revenue 0.0 · Net income -28.3
-100M-200M
201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2015 · Operating -33063.0%
-10000%-20000%-30000%
201020172025
ROE
FY2023 · ROE -79.1%
-50%-100%-150%
201020172025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

USD 229,000.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2019 · FCF -3.7
-5M-10M
201020172025
Net buybacks $ Dividends $
FY2025 · Dividends 229000.0 · Net buybacks ·
100000200000
2025

USD 229,000.00 in dividends went back to shareholders in a year without profit.

Total assetsUSD 8.1M
EquityUSD 5.8M
CashUSD 6.8M
Current ratio3.50×

Equity funds 71% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GTBP, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B◌◌◌◌◌0.00.0◌0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.00.0−0.3−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌◌◌◌◌−0.00.0−0.3−0.1−0.0−0.0−0.0◌◌◌◌
Income tax $B◌◌◌◌◌◌0.00.00.00.00.00.00.00.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.3−0.10.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌◌◌◌◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
EPS, diluted $−6.68−6.94−5.64−19.66−2.06−6.45−0.01−5.16−8.60119.91−8.96−0.04−0.01−0.01−0.02−0.03
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %−1———————————————
ROE %——−79.1−124.1———−197.1————————
Shares out B0.030.000.000.030.030.010.070.050.050.000.000.000.570.500.270.15

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure · 1 divergence in 71 reconciliationsAUDITED

Reconciled in 14 of the 16 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image